Granisetron

Generic Name
Granisetron
Brand Names
Sancuso, Sustol
Drug Type
Small Molecule
Chemical Formula
C18H24N4O
CAS Number
109889-09-0
Unique Ingredient Identifier
WZG3J2MCOL
Background

A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.

Indication

For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).

Associated Conditions
Nausea and vomiting
Associated Therapies
-
Clinical Trials
Related News

Effect of Granisetron on Morphine Induced Pruritus in Cesarean Section

First Posted Date
2018-03-30
Last Posted Date
2021-09-09
Lead Sponsor
Assiut University
Target Recruit Count
80
Registration Number
NCT03483870
Locations
🇪🇬

Assiut University Hospital, Assiut, Egypt

Comp Granisetron Midazolam Comb in Lap Children

First Posted Date
2018-03-30
Last Posted Date
2018-03-30
Lead Sponsor
Assiut University
Target Recruit Count
90
Registration Number
NCT03483350

Aromatherapy for Prevention of Intrathecal Morphine Induced Nausea and Vomiting

First Posted Date
2018-02-15
Last Posted Date
2019-04-18
Lead Sponsor
Universiti Kebangsaan Malaysia Medical Centre
Target Recruit Count
155
Registration Number
NCT03434340
Locations
🇲🇾

Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia

Treatment Algorithm for Nausea and Vomiting in the Palliative Phase

First Posted Date
2017-01-11
Last Posted Date
2017-01-11
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
20
Registration Number
NCT03017391

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Not Applicable
Completed
Conditions
Postoperative Nausea and Vomiting
Interventions
Procedure: Automated recommendation at the start of the case
Procedure: Automated notification at the start of surgery
Procedure: Automated notification at the end of surgery
Device: Anesthesia Information Management System (AIMS)
Device: Perioperative Data Warehouse (PDW)
Procedure: General anesthesia
Procedure: Elective surgery
Drug: Propofol
Drug: Sevoflurane
Drug: Isoflurane
Drug: Desflurane
Drug: Scopolamine
Drug: Droperidol
Drug: Haloperidol
Drug: Dexamethasone
Drug: Promethazine
Drug: Meclizine
Drug: Aprepitant
Drug: Metoclopramide
Drug: Fentanyl
Drug: Sufentanil
Drug: Alfentanil
Drug: Remifentanil
Drug: Morphine
Drug: Meperidine
Drug: Hydromorphone
Drug: Methadone
Drug: Oxycodone
Drug: Oxymorphone
Drug: Hydrocodone
Drug: Ketamine
Drug: Ondansetron
Drug: Granisetron
Drug: Dolasetron mesylate
Drug: Palonosetron
Drug: Tropisetron
Drug: Ramosetron
First Posted Date
2015-12-09
Last Posted Date
2019-03-07
Lead Sponsor
Vanderbilt University
Target Recruit Count
27034
Registration Number
NCT02625181
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Prevention of Spinal Induced Shivering During CS

First Posted Date
2015-10-28
Last Posted Date
2017-11-17
Lead Sponsor
Assiut University
Target Recruit Count
212
Registration Number
NCT02588547
Locations
🇪🇬

Seham Mohamed Moeen Ibrahim, Asyut, Egypt

Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting

Phase 2
Completed
Conditions
Postoperative Nausea and Vomiting
Interventions
Drug: granisetron
First Posted Date
2015-05-29
Last Posted Date
2019-12-18
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
50
Registration Number
NCT02457195
Locations
🇺🇸

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles

First Posted Date
2014-09-03
Last Posted Date
2021-03-24
Lead Sponsor
Karolinska Institutet
Target Recruit Count
40
Registration Number
NCT02230371
Locations
🇸🇪

Karolinska Institutet, Department of Dental Medicine, Huddinge, Sweden

Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients

Phase 2
Withdrawn
Conditions
Malignant Glioma
Interventions
Drug: Granisetron
Drug: Ondansetron
First Posted Date
2013-09-30
Last Posted Date
2014-09-22
Lead Sponsor
Duke University
Registration Number
NCT01952886
Locations
🇺🇸

Duke Cancer Center, Durham, North Carolina, United States

The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy

First Posted Date
2013-07-29
Last Posted Date
2015-12-04
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Target Recruit Count
92
Registration Number
NCT01909856
Locations
🇨🇳

Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy